

A recombinant adenovirus type-5 vectored COVID-19 vaccine appears safe and immunogenic in a first-inhuman trial.





mining before and after extendion Construction No. This and the month No. This and the construction

iii To ally producing any entropy of the Ally produced by the Ally produced by the Experiments, with 2019 of other process. Scientificants (With Annual Scientificants (With Annual

Zhu et al., 2020 the Lancet

A replication defective Ad5 vectored vaccine expressing the spike glycoprotein of SARS-CoV-2 based on the full-length spike gene from the Wuhan-Hu-1 strain was given to three groups of volunteers at different doses (thirty six volunteers in each group). A single shot was allocated intramuscularly in the arm of the participants in the low dose group (5×10 10 viral particles per 0.5 mL). The participants in the middle dose group received one shot intramuscularly in the arm $(1 \times 10^{11} \text{ viral particles per mL})$. Participants in the high dose group received a double-shot regimen with one vial of the Ad5 vectored COVID-19 vaccine in one arm and two vials of the Ad5 vectored COVID-19 vaccine in the other arm $(1.5 \times 10^{11} \text{ viral})$ particles per 1.5 mL). The most common injection site adverse reaction was pain, reported in 58 (54%) vaccine recipients, and the most commonly reported systematic adverse reactions were fever (50 [46%]), fatigue (47 [44%]), headache (42 [39%]), and muscle pain (18 [17%]. Most adverse reactions that were reported in all dose groups were mild or moderate in severity. No serious adverse event was noted within 28 days post-vaccination. The vaccine elicited specific antibody responses to the receptor binding domain as well as neutralizing antibodies to live SARS-CoV-2, with the high does group showing higher antibody titres than the lower dose groups. T cell responses were assessed using the IFNy ELISPOT assay and appeared to peak at day 14 after vaccination, with responses correlating with vaccine doses. Both CD4+ and CD8+ T cells showed some degree of IFNy-TNFa-IL-2 polyfunctional responses at day 14 after vaccination, with either IFNy or TNFa predominating as single or dual-expressing CD8+ and CD4+ T cells, respectively. The authors state in conclusion that "we found that the Ad5 vectored COVID-19 vaccine is tolerable and immunogenic in healthy adults. Specific humoral responses against SARS-CoV-2 peaked at day 28 post-vaccination, and rapid, specific T-cell responses were noted from day 14 after one shot of the vaccine."

Journal Article: Zhu, Li et al., 2020. <u>Safety, tolerability,</u> and immunogenicity of a recombinant adenovirus type-5 vectored <u>COVID-19 vaccine: a dose-escalation, open-label, non-</u> <u>randomised, first-in-human trial.</u> the Lancet

Summary by Clive Gray